Tomizawa Y - Search Results

1

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.

Kotake M, Miura Y, Imai H, Mori K, Sakurai R, Kaira K, Tomizawa Y, Minato K, Saito R, Hisada T. Kotake M, et al. Among authors: tomizawa y. Chemotherapy. 2017;62(4):205-213. doi: 10.1159/000456534. Epub 2017 Apr 6. Chemotherapy. 2017. PMID: 28380484

2

[Rapid progression of adenocarcinoma of the lung in a patient with high levels of granulocyte colony-stimulating factor].

Tomizawa Y, Kuroiwa H, Suda T, Muroda N, Ezawa K, Minato K, Dobashi K, Tsuchiya S, Saito R, Mori M. Tomizawa Y, et al. Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Nov;34(11):1249-54. Nihon Kyobu Shikkan Gakkai Zasshi. 1996. PMID: 8976082 Japanese.

3

Identification and characterization of families with aggregation of lung cancer.

Tomizawa Y, Adachi J, Kohno T, Yamaguchi N, Saito R, Yokota J. Tomizawa Y, et al. Jpn J Clin Oncol. 1998 Mar;28(3):192-5. doi: 10.1093/jjco/28.3.192. Jpn J Clin Oncol. 1998. PMID: 9614442

4

Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.

Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Tomizawa Y, et al. Cancer Res. 1998 Dec 1;58(23):5478-83. Cancer Res. 1998. PMID: 9850082

5

Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.

Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J. Tomizawa Y, et al. Oncogene. 1999 Jan 28;18(4):1007-14. doi: 10.1038/sj.onc.1202384. Oncogene. 1999. PMID: 10023676

6

Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.

Tomizawa Y, Adachi J, Kohno T, Hamada K, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Yokota J. Tomizawa Y, et al. Clin Cancer Res. 1999 May;5(5):1139-46. Clin Cancer Res. 1999. PMID: 10353749

7

Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.

Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J. Tomizawa Y, et al. Clin Cancer Res. 2002 Jul;8(7):2362-8. Clin Cancer Res. 2002. PMID: 12114441

8

Allelic losses on chromosome 3p are accumulated in relation to morphological changes of lung adenocarcinoma.

Iijima H, Tomizawa Y, Dobashi K, Saito R, Nakajima T, Mori M. Iijima H, et al. Among authors: tomizawa y. Br J Cancer. 2004 Sep 13;91(6):1143-8. doi: 10.1038/sj.bjc.6602005. Br J Cancer. 2004. PMID: 15292942 Free PMC article.

9

Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.

Tomizawa Y, Iijima H, Nomoto T, Iwasaki Y, Otani Y, Tsuchiya S, Saito R, Dobashi K, Nakajima T, Mori M. Tomizawa Y, et al. Lung Cancer. 2004 Dec;46(3):305-12. doi: 10.1016/j.lungcan.2004.05.003. Lung Cancer. 2004. PMID: 15541815

10

Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers.

Iijima H, Tomizawa Y, Iwasaki Y, Sato K, Sunaga N, Dobashi K, Saito R, Nakajima T, Minna JD, Mori M. Iijima H, et al. Among authors: tomizawa y. Int J Cancer. 2006 Feb 15;118(4):797-801. doi: 10.1002/ijc.21462. Int J Cancer. 2006. PMID: 16152584

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

431 results

Search Page

Filters